Kavita Raniga, Aishah Nasir, Nguyen T N Vo, Ravi Vaidyanathan, Sarah Dickerson, Simon Hilcove, Diogo Mosqueira, Gary R Mirams, Peter Clements, Ryan Hicks, Amy Pointon, Will Stebbeds, Jo Francis, Chris Denning
{"title":"利用人体多能干细胞衍生的心肌细胞加强心脏治疗管道。","authors":"Kavita Raniga, Aishah Nasir, Nguyen T N Vo, Ravi Vaidyanathan, Sarah Dickerson, Simon Hilcove, Diogo Mosqueira, Gary R Mirams, Peter Clements, Ryan Hicks, Amy Pointon, Will Stebbeds, Jo Francis, Chris Denning","doi":"10.1016/j.stem.2024.01.007","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.</p>","PeriodicalId":93928,"journal":{"name":"Cell stem cell","volume":" ","pages":"292-311"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes.\",\"authors\":\"Kavita Raniga, Aishah Nasir, Nguyen T N Vo, Ravi Vaidyanathan, Sarah Dickerson, Simon Hilcove, Diogo Mosqueira, Gary R Mirams, Peter Clements, Ryan Hicks, Amy Pointon, Will Stebbeds, Jo Francis, Chris Denning\",\"doi\":\"10.1016/j.stem.2024.01.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.</p>\",\"PeriodicalId\":93928,\"journal\":{\"name\":\"Cell stem cell\",\"volume\":\" \",\"pages\":\"292-311\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell stem cell\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.stem.2024.01.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell stem cell","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.stem.2024.01.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/15 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes.
Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.